Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Singh S et al.
Nature, 2025
40836083 (PubMed )
Supplement: 41586_2025_9433_MOESM4_ESM.zip › 2024-07-15654B-s4 › Table_S5_052925.xlsx › Tab_7-zscore_CDK2_A_G
Intra-S phase checkpoint kinase Chk1 dissociates replication proteins Treslin and TopBP1 through multiple mechanisms during replication stress.
Kelly RL et al.
The Journal of Biological Chemistry, 2022
Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ et al.
Journal of Medicinal Chemistry, 2006
Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells.
Matsusaka T et al.
The Journal of Cell Biology, 2004
Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop.
Bártová I et al.
Protein Science : a Publication of the Protein Society, 2004
Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.
Chow JP et al.
The Journal of Biological Chemistry, 2003
Select a paper to view details